208 related articles for article (PubMed ID: 23159116)
41. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
[TBL] [Abstract][Full Text] [Related]
42. Melanoma.
Schadendorf D; Fisher DE; Garbe C; Gershenwald JE; Grob JJ; Halpern A; Herlyn M; Marchetti MA; McArthur G; Ribas A; Roesch A; Hauschild A
Nat Rev Dis Primers; 2015 Apr; 1():15003. PubMed ID: 27188223
[TBL] [Abstract][Full Text] [Related]
43. BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential.
Seitz-Alghrouz R; Hidalgo JV; Kayser C; Kreutz C; Technau-Hafsi K; Diaz C; von Deimling A; Timmer J; Werner M; Malkovsky M; Fisch P
J Invest Dermatol; 2018 Nov; 138(11):2489-2491. PubMed ID: 29775633
[No Abstract] [Full Text] [Related]
44. Mutations in g protein encoding genes and chromosomal alterations in primary leptomeningeal melanocytic neoplasms.
Küsters-Vandevelde HV; van Engen-van Grunsven IA; Coupland SE; Lake SL; Rijntjes J; Pfundt R; Küsters B; Wesseling P; Blokx WA; Groenen PJ
Pathol Oncol Res; 2015 Apr; 21(2):439-47. PubMed ID: 25315378
[TBL] [Abstract][Full Text] [Related]
45. Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
Urso C
Am J Dermatopathol; 2019 Sep; 41(9):623-629. PubMed ID: 31433323
[TBL] [Abstract][Full Text] [Related]
46. Protein expression of KIT, BRAF, GNA11, GNAQ and RASSF1 in feline diffuse iris melanomas.
Rushton JG; Korb M; Kummer S; Reichart U; Fuchs-Baumgartinger A; Tichy A; Nell B
Vet J; 2019 Jul; 249():33-40. PubMed ID: 31239162
[TBL] [Abstract][Full Text] [Related]
47. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
[TBL] [Abstract][Full Text] [Related]
48. The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.
Ominato J; Fukuchi T; Sato A; Yamaguchi N; Kobayashi K; Cho H; Oyama T; Ajioka Y
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):658-663. PubMed ID: 28248732
[TBL] [Abstract][Full Text] [Related]
49. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis.
Sheng X; Kong Y; Li Y; Zhang Q; Si L; Cui C; Chi Z; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Dai J; Guo J
Eur J Cancer; 2016 Sep; 65():156-63. PubMed ID: 27498141
[TBL] [Abstract][Full Text] [Related]
50. Molecular alterations in malignant blue nevi and related blue lesions.
Yilmaz I; Gamsizkan M; Sari SO; Yaman B; Demirkesen C; Heper A; Calli AO; Narli G; Kucukodaci Z; Berber U; Demirel D; Akalin T; Demiriz M; Buyukbabani N
Virchows Arch; 2015 Dec; 467(6):723-732. PubMed ID: 26403583
[TBL] [Abstract][Full Text] [Related]
51. Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis.
Küsters-Vandevelde HV; van Engen-van Grunsven IA; Küsters B; van Dijk MR; Groenen PJ; Wesseling P; Blokx WA
Acta Neuropathol; 2010 Dec; 120(6):755-64. PubMed ID: 20865267
[TBL] [Abstract][Full Text] [Related]
52. Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma.
Aksenenko MB; Kirichenko AK; Ruksha TG
Pathol Res Pract; 2015 Jul; 211(7):521-7. PubMed ID: 25888143
[TBL] [Abstract][Full Text] [Related]
53. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
Uribe P; Andrade L; Gonzalez S
J Invest Dermatol; 2006 Jan; 126(1):161-6. PubMed ID: 16417232
[TBL] [Abstract][Full Text] [Related]
54. The T1799A BRAF mutation is present in iris melanoma.
Henriquez F; Janssen C; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
[TBL] [Abstract][Full Text] [Related]
55. GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi.
Vader MJC; Madigan MC; Versluis M; Suleiman HM; Gezgin G; Gruis NA; Out-Luiting JJ; Bergman W; Verdijk RM; Jager MJ; van der Velden PA
Br J Cancer; 2017 Sep; 117(6):884-887. PubMed ID: 28809862
[TBL] [Abstract][Full Text] [Related]
56. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
Thomas NE
Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
[TBL] [Abstract][Full Text] [Related]
57. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
Varada S; Mahalingam M
Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
[TBL] [Abstract][Full Text] [Related]
58. Blue nevi and variants: an update.
Zembowicz A; Phadke PA
Arch Pathol Lab Med; 2011 Mar; 135(3):327-36. PubMed ID: 21366456
[TBL] [Abstract][Full Text] [Related]
59. BRAF analysis on a spectrum of melanocytic neoplasms: an epidemiological study across differing UV regions.
Saroufim M; Habib R; Karram S; Youssef Massad C; Taraif S; Loya A; Houreih MA; Sheikh SS; Amr SS; Satti M; Oberkanins C; Khalifeh I
Am J Dermatopathol; 2014 Jan; 36(1):68-73. PubMed ID: 23782679
[TBL] [Abstract][Full Text] [Related]
60. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi.
Salgado CM; Basu D; Nikiforova M; Bauer BS; Johnson D; Rundell V; Grunwaldt LJ; Reyes-Múgica M
Pediatr Dev Pathol; 2015; 18(1):1-9. PubMed ID: 25490715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
